News & Updates
Filter by Specialty:
Milvexian prevents VTE after knee arthroplasty, bleeding risk low
Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.
Milvexian prevents VTE after knee arthroplasty, bleeding risk low
02 Dec 2021
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
Remnant cholesterol tied to CVD death in patients with T2D, CKD, diabetic nephropathy
Remnant cholesterol (C) appears predictive of mortality due to cardiovascular disease (CVD) among patients with type 2 diabetes (T2D), chronic kidney disease (CKD) stage 3 to 5, and incident diabetic nephropathy (DN), suggests a study.
Remnant cholesterol tied to CVD death in patients with T2D, CKD, diabetic nephropathy
29 Nov 2021
Add-on ezetimibe helps reduce LDL-C in post-ACS patients
The addition of ezetimibe to a statin led to reductions in low-density lipoprotein-cholesterol (LDL-C) in patients who have been stabilized after the presentation of an acute coronary syndrome (ACS), according to data presented at AHA 2021.